An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered for 4 weeks as an add-on to patients, in ACE inhibitor or angiotensin II receptor blocker treatment, with idiopathic.

A randomized, double-blinded, placebo-controlled phase 2 study with inclusion of patients with nephrotic syndrome and Idiopathic Membranous Nephropathy diagnosed as anti-PLA2-Receptor positive prior to inclusion. The study will examine the safety of an investigatory drug evaluating adverse events and serious adverse events. Furthermore, change in urine protein excretion in 24 hours is evaluated.

Researchers:

• Sarah Kelddal
• Henrik Birn
• Per Ivarsen